Vedanta Biosciences is a cutting-edge biotech startup that operates in the rapidly evolving field of microbiome therapies. The company's primary focus is on the discovery and development of drugs based on bacterial consortia, which are groups of bacteria that work together for mutual benefit. These bacteria have drug-like properties and can colonize the human intestine, potentially offering a new way to treat a variety of diseases.

Vedanta's business model revolves around its proprietary discovery platform. This platform allows the company to identify beneficial bacteria and assemble them into rationally-designed consortia, or teams of bacteria, that can have optimal therapeutic activity. This innovative approach to drug discovery could potentially revolutionize the way diseases are treated.

The company serves a broad range of clients, including doctors and patients who are seeking new treatment options for various diseases. Vedanta's market is the global healthcare industry, specifically the segment focused on innovative drug therapies.

Vedanta generates revenue by developing and commercializing its drug candidates. The company is the first to achieve commercial-scale CGMP (Current Good Manufacturing Practice) production of drug candidates based on defined bacterial consortia. CGMP refers to the regulations enforced by the US Food and Drug Administration (FDA) to ensure that the drugs produced are safe and meet specified quality standards.

In summary, Vedanta Biosciences is a pioneering biotech company that is leveraging the power of bacterial consortia to develop innovative new drugs. The company's unique approach to drug discovery could potentially transform the healthcare industry and provide patients with new treatment options.

Keywords: Vedanta Biosciences, biotech startup, microbiome therapies, bacterial consortia, drug discovery, healthcare industry, innovative drug therapies, CGMP production, bacterial drug candidates, treatment options.